Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 v2.3.0.11
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 3 Months Ended 9 Months Ended
Jun. 30, 2011
Jun. 30, 2010
Jun. 30, 2011
Jun. 30, 2010
REVENUES        
Neurometric information services $ 25,000 $ 39,900 $ 81,400 $ 96,700
Clinical services 172,800 119,300 456,000 384,300
Sales Revenue, Services, Net 197,800 159,200 537,400 481,000
OPERATING EXPENSES        
Cost of neurometric services revenues 37,800 32,800 110,300 101,900
Research and development 181,800 302,400 772,900 843,600
Sales and marketing 366,600 201,600 960,900 603,800
General and administrative 1,060,700 1,081,700 3,193,800 3,639,900
Total operating expenses 1,646,900 1,618,500 5,037,900 5,189,200
OPERATING LOSS (1,449,100) (1,459,300) (4,500,500) (4,708,200)
OTHER INCOME (EXPENSE):        
Interest income (expense), net (2,117,100) (40,900) (6,073,200) (42,600)
Financing fees (59,300) 0 (348,500) 0
Gain (Loss) on derivative liabilities 4,498,900 0 4,753,100 0
Total other income (expense) 2,322,500 (40,900) (1,668,600) (42,600)
PROFIT (LOSS) BEFORE PROVISION FOR INCOME TAXES 873,400 (1,500,200) (6,169,100) (4,750,800)
Income taxes 0 0 1,300 2,400
NET PROFIT (LOSS) $ 873,400 $ (1,500,200) $ (6,170,400) $ (4,753,200)
NET PROFIT (LOSS) PER SHARE:        
Basic (Note 7) (in dollars per share) $ 0.02 $ (0.03) $ (0.11) $ (0.09)
Diluted (Note 7) (in dollars per share) $ 0.02 $ (0.03) $ (0.11) $ (0.09)
WEIGHTED AVERAGE SHARES OUTSTANDING:        
Basic (in shares) 56,117,600 56,023,921 56,055,147 51,028,185
Diluted (in shares) 56,117,600 56,023,921 56,055,147 51,028,185